Fastest Growing Stocks
ARGX.BR is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
ARGENX SE (ARGX.BR) Stock Price & Overview
EBR:ARGX • NL0010832176
Current stock price
716.8 EUR
+6.2 (+0.87%)
Last:
The current stock price of ARGX.BR is 716.8 EUR. Today ARGX.BR is up by 0.87%. In the past month the price increased by 15.36%. In the past year, price increased by 35.56%.
ARGX.BR Key Statistics
52-Week Range456.6 - 810
Current ARGX.BR stock price positioned within its 52-week range.
1-Month Range568.4 - 720.2
Current ARGX.BR stock price positioned within its 1-month range.
- Market Cap
- 44.356B
- P/E
- 43.26
- Fwd P/E
- 31.12
- EPS (TTM)
- 16.57
- Dividend Yield
- N/A
ARGX.BR Stock Performance
Today
+0.87%
1 Week
+5.03%
1 Month
+15.36%
3 Months
+2.45%
Longer-term
6 Months -0.17%
1 Year +35.56%
2 Years +102.57%
3 Years +103.79%
5 Years +195.59%
10 Years +5,999.57%
ARGX.BR Stock Chart
ARGX.BR Stock Screens
ARGX.BR currently appears in the following ChartMill screener lists.
Revenue Growth Leaders
ARGX.BR is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
RSI Overbought Stocks
ARGX.BR is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
CAN SLIM Stocks
ARGX.BR is part of our CAN SLIM stock list, indicating it is suited for high growth momentum investing and is a technical leader.
High EPS Growth Stocks
ARGX.BR occurs in our High EPS Growth Stocks screen list, indicating it is profitable, healthy and showing strong recent EPS growth.
ARGX.BR Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ARGX.BR. When comparing the yearly performance of all stocks, ARGX.BR is one of the better performing stocks in the market, outperforming 76.84% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ARGX.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to ARGX.BR. ARGX.BR has an excellent financial health rating, but there are some minor concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ARGX.BR Earnings
On February 26, 2026 ARGX.BR reported an EPS of 8.02 and a revenue of 1.32B. The company beat EPS expectations (28.35% surprise) and beat revenue expectations (0.3% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported$8.02
Revenue Reported1.322B
EPS Surprise 28.35%
Revenue Surprise 0.30%
ARGX.BR Forecast & Estimates
25 analysts have analysed ARGX.BR and the average price target is 893.75 EUR. This implies a price increase of 24.69% is expected in the next year compared to the current price of 716.8.
For the next year, analysts expect an EPS growth of 39.01% and a revenue growth 40.86% for ARGX.BR
Analysts
Analysts84.8
Price Target893.75 (24.69%)
EPS Next Y39.01%
Revenue Next Year40.86%
ARGX.BR Groups
Sector & Classification
ARGX.BR Financial Highlights
Over the last trailing twelve months ARGX.BR reported a non-GAAP Earnings per Share(EPS) of 16.57. The EPS increased by 1028.32% compared to the year before.
Income Statements
Revenue(TTM)7.02B
Net Income(TTM)2.05B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 29.23% | ||
| ROA | 23.62% | ||
| ROE | 28.01% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%762.37%
Sales Q2Q%73.67%
EPS 1Y (TTM)1028.32%
Revenue 1Y (TTM)220.39%
ARGX.BR Ownership
Ownership
Inst Owners45.26%
Shares61.88M
Float61.87M
Ins Owners0.12%
Short Float %N/A
Short RatioN/A
ARGX.BR Competitors/Peers
The largest stocks on the EU markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 30.82 | 43.922B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.571B | ||
| ABVX | ABIVAX SA | N/A | 8.183B | ||
| 2X1 | ABIVAX SA | N/A | 8.167B | ||
| GLPG | GALAPAGOS NV | N/A | 1.612B | ||
| GXE | GALAPAGOS NV | N/A | 1.612B | ||
| NANO | NANOBIOTIX | N/A | 1.348B | ||
| PHGN | PHARMING GROUP NV | 49.88 | 1.052B | ||
| PHARM | PHARMING GROUP NV | 49.28 | 1.045B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 991.483M | ||
| IVA | INVENTIVA SA | N/A | 984.545M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 983.689M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Brussels Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find more growth stocks the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ARGX.BR
Company Profile
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Company Info
IPO: 2014-07-10
ARGENX SE
Laarderhoogtweg 25
Amsterdam NOORD-HOLLAND NL
Employees: 1863
Phone: 31763030
ARGENX SE / ARGX.BR FAQ
What does ARGX do?
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Can you provide the latest stock price for ARGENX SE?
The current stock price of ARGX.BR is 716.8 EUR. The price increased by 0.87% in the last trading session.
Does ARGX stock pay dividends?
ARGX.BR does not pay a dividend.
How is the ChartMill rating for ARGENX SE?
ARGX.BR has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Where is ARGENX SE (ARGX.BR) stock traded?
ARGX.BR stock is listed on the Euronext Brussels exchange.
What is the analyst forecast for ARGX.BR stock?
25 analysts have analysed ARGX.BR and the average price target is 893.75 EUR. This implies a price increase of 24.69% is expected in the next year compared to the current price of 716.8.
Can you provide the growth outlook for ARGENX SE?
The Revenue of ARGENX SE (ARGX.BR) is expected to grow by 40.86% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.